study provided a large-scale assessment of psychosocial issues in 675 adults with moderate-severe hemophilia A and B, and found that most participants experienced pain that interfered with their daily life in the past 4 weeks. 3 Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study, which assessed the impact of pain in 381 individuals with hemophilia and a history of joint pain or bleeding, indicated that participants reporting pain were more likely to experience anxiety and depression, worse health status, and functional impairment. 4 Furthermore, post hoc analyses suggest that independent of joint status (measured using the Hemophilia Joint Health Score v2.1), greater pain severity and interference as measured by the Brief Pain Inventory v2 Short Form (BPI)
were associated with unemployment, use of opioids, use of anxiolytics, and self-reported anxiety/depression. 7 Additionally, functional impairment as measured by the Hemophilia Activities List (HAL) was associated with similar factors (ie, older age, unemployment, inhibitor status, and use of anxiolytics) and greater pain severity. 8 Despite these recent advancements in our understanding of HRQoL and related outcomes in individuals with hemophilia, data specific to the subpopulation of individuals with hemophilia B are limited.
Hemophilia B is less common than hemophilia A, as individuals with hemophilia B account for approximately 15%-20% of the overall hemophilia population (~5000 of ~21 000 US patients seen in treatment centers according to recent population profiles). 1, 9 Therefore, participation in previous studies consisted of large majorities of individuals with hemophilia A. For example, in the HERO study, which was one of the largest studies of HRQoL in people with hemophilia, individuals with hemophilia B accounted for only 13% of adults and 16% of children (described by their caregivers). 10 In addition, women and girls with hemophilia have been underrepresented in hemophilia clinical trials, as they generally exhibit milder symptoms, and being a carrier has historically not been considered to be associated with bleeding.
The Bridging Hemophilia B Experiences, Results, and
Opportunities Into Solutions (B-HERO-S) study was designed to build upon the HERO study by evaluating psychosocial issues and HRQoL in the hemophilia B population specifically, including women with hemophilia B and caregivers of children with hemophilia B. In addition, the study was open to individuals with any hemophilia severity and thus included those with mild and moderate hemophilia B. Previous reports from B-HERO-S have described the psychosocial impact of hemophilia B on affected individuals, including the impact on employment, education, and participation in recreational activities. [11] [12] [13] Of note, while very rapid recruitment through 3 patient advocacy organizations may be expected to have biased the study population toward those most affected, B-HERO-S captured a substantial proportion of US hemophilia B patients (~4% of adults with mild and ~10% of adults with moderate hemophilia B). Most of the 299 adult participants indicated that hemophilia B had a negative impact on their work life, education, and ability to participate in recreational activities, suggesting that overall HRQoL may be impaired in individuals with hemophilia B. Furthermore, most of the 150 caregivers of children with hemophilia B (boys or girls, aged <18 years)
reported that hemophilia affected their children's education, relationships, and physical activity, as well as their other children and the caregiver's/partner's employment. Here, we report the results of 6 patient-reported outcome (PRO) instruments administered in the B-HERO-S study to adult patients and/or caregivers. We used both generic and disease-specific PRO instruments to broadly characterize psychological issues, pain, functional ability, and quality of life.
| ME THODS

| Study design
The B-HERO-S study methods were previously described in detail. 13 In brief, participants were recruited in the United States via email and social media outlets through 3 patient advocacy or- 
| PRO instruments
EQ-5D-5L measures overall health status "today" and is composed of 2 segments, a descriptive portion and a VAS. The descriptive section assesses 5 dimensions (mobility, self-care, usual activities, pain/ discomfort, and anxiety/depression). 14, 15 Index scores are calculated based on responses to each section and population-specific normative data using the EuroQoL index value calculator. 16 The VAS portion consists of an electronic version of the 20-cm printed scale.
Participants are instructed to indicate their health state "today" using a 100-point scale with end points labeled as "worst health you
can imagine" at 0 and "best health you can imagine" at 100.
Brief Pain Inventory v2 Short Form evaluates pain severity and interference in the past 7 days. Scores range from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "complete interference"). BPI severity scores reported here were calculated as averages of 4 severity domains (worst pain, least pain, average pain, 
| Statistical analysis
Results from each distinct survey (one for patients and one for caregivers) were analyzed separately. Data management was administered by Huron Consulting Services under the guidance of Novo Nordisk
Inc. Statistical analyses were completed using Toluna Analytics version 5.0 (Dallas, TX, USA) on de-identified data from patient and caregiver analysis sets. Scores for PRO instruments were analyzed according to standardized protocols, as described above. 15, 17, 18, 20, 21 Data from the PRO instruments were summarized for both patient and caregiver analysis sets. Descriptive statistics (frequency distributions, numbers of respondents, minimums, maximums, means, medians, and quartiles [Q1, Q3]) were calculated for all variables.
| RE SULTS
| Participant demographics
In total, 299 adults with hemophilia B and 150 caregivers of children with hemophilia B participated in the B-HERO-S study (Table 1) .
Median age of adult participants with hemophilia was 29 years, and 29% were women. Most (63%) had moderate hemophilia B; fewer had mild hemophilia B (25%) or severe hemophilia B (11%). Most adults (80%) were receiving some form of routine factor infusions at various frequencies to prevent bleeding, and 20% were treated for bleeding on-demand or mostly on-demand. The majority of adults and caregivers reported modifying treatment around activity. 11 Most participating adults with hemophilia were employed (81%). Selfreported comorbidities described by participants as related to their hemophilia included arthritis (48%), acute/intermittent pain (29%), anxiety (23%), depression (22%), and chronic/persistent pain (13%).
All caregiver participants were parents of children with hemophilia B, a majority of whom were mothers (77%). The median age of caregivers was 35 years, and the median age of the children pertaining to the study was 10 years. Most caregivers were employed (86%).
| EQ-5D-5L in adults with hemophilia
On EQ-5D-5L, adults with hemophilia B commonly reported having moderate or severe problems with pain/discomfort (47%), anxiety/ depression (41%), and usual activities (41%) ( Figure 1A ). Smaller percentages reported moderate or severe problems with mobility (19%) and self-care (20%). Most respondents with moderate hemophilia reported problems across the 5 domains, and more women than men reported problems with anxiety/depression (Table S1 ).
Overall, median (Q1, Q3) EQ-5D VAS score was 50 (42, 66), on a scale of 0-100, with higher scores indicating better quality of life 
| BPI in adults with hemophilia
Overall, most adult respondents with hemophilia reported some degree of pain (scores other than 0). Slightly more than half (57%) rated their current pain severity between 1 and 6 (higher scores indicate greater pain severity), and median BPI pain severity composite score was 5 ( Figure 2A ). Women had a higher median (Q1, Q3)
BPI pain severity score than men (7. 
| IPAQ in adults with hemophilia
On IPAQ, 94% of adults with hemophilia reported some activity during the past week. Nearly all (92%) reported time (>10 minutes) spent 
| HAL in adults with hemophilia
Hemophilia Activities List scores were similar across all 10 domains and the overall sum score. Median overall HAL score was 60 (on a scale of 0-100, with higher scores indicating better functional status) for each of the composite indexes of upper extremity activities, basic lower extremity activities, complex lower extremity activities, and overall score ( Figure 3 ). Although ranges for HAL overall and composite index scores were individually widely distributed, aggregate (means/medians) scores were relatively consistent across age, gender, and hemophilia severity (Table S2 ).
| PHQ-9 in adults with hemophilia
For adults with hemophilia, median (Q1, Q3) score for PHQ-9 was 8 (0, 12) (higher scores indicate more severe depression), and most (62%) had a PHQ-9 score of at least 5 (indicating at least mild depression) ( Table 2 ). Women had a higher median (Q1, Q3) score than men (11 [8, 13] 
vs 6 [0, 12]). Most adults with severe hemo-
philia had a PHQ -9 score of ≥5 (80%), compared with 66% of those with moderate hemophilia and 40% of those with mild hemophilia.
| PHQ-9 and GAD-7 in caregivers
Overall, approximately half (53%) of caregivers had a PHQ-9 score of 5 or greater (Table 3) . Mothers had a higher PHQ-9 median (Q1, Q3) score than fathers (8 [2, 12] vs 2 [0, 5]), and more than twice as many mothers compared with fathers had a PHQ-9 score of ≥5 (mothers, 60%; fathers, 27%). Caregivers of children with moderate hemophilia had a higher median (Q1, Q3) score (11 [3, 12] On GAD-7, median (Q1, Q3) score for caregivers was 4 (1, 9) and 47% had a score of at least 5, indicative of at least mild anxiety. Sixty-eight percent of caregivers of children with moderate hemophilia had GAD-7 scores of ≥5, compared with 18% whose children had mild hemophilia and 21% whose children had severe hemophilia. Overall, mothers had a higher median (Q1, Q3) score (6 [2, 10] ) than fathers (2 [0, 4]).
| D ISCUSS I ON
The B-HERO-S study was developed to obtain a better understanding of the experiences of adults with hemophilia B and children FI G U R E 1 A, EQ-5D-5L in adults with hemophilia B. B, EQ-5D VAS. C, EQ-5D-5L index may experience delays in treatment due to a lack of bleed recognition or inability to rapidly self-manage bleeding episodes (only 18% of adults in B-HERO-S were able to self-infuse), leading to an increased incidence of hemophilia-related arthritic complications that cause pain. [34] [35] [36] Potential differences in people with mild or moderate vs severe hemophilia in the trend for proactive vs reactive approaches to routine management of hemophilia, frequency of routine health care visits, and extent of proactive pain management may also contribute to high levels of self-reported pain among those with mild or moderate disease. Of note, respondents who were treated ondemand had a lower median BPI pain severity score than those on routine infusions (2.75 vs 6.00), which perhaps reflects more mild disease in respondents who treated on-demand.
Considering the high levels of pain and depression reported by individuals with moderate hemophilia B, it is not surprising that this group reported worse overall health status compared with those with mild and severe hemophilia B. Both the health index scores and VAS ratings of health status were lower in patients with moderate hemophilia B. These data highlight the comparatively poor outcomes for respondents with moderate hemophilia and suggest that this population may be more affected by pain and mental health issues than previously recognized. Interestingly, respondents with ondemand treatment regimens had a higher median EQ-5D-5L index score (0.83 vs 0.66 for those on routine infusions) and VAS score (70.0 vs 48.0 for those on routine infusions). Lower quality of life in respondents who were on some form of routine infusions may be due to a greater prevalence of bleeding issues in this group as a potential reason for changing to a prophylaxis regimen.
F I G U R E 3 HAL in adults with hemophilia
A unique attribute of the B-HERO-S study was the inclusion of women with hemophilia B, which provided the opportunity to identify unmet needs in this population. Notably, median BPI pain severity score was higher for women with hemophilia B than for men (7.0 vs 5.0, respectively), despite having much more similar self-reported functional abilities (HAL overall score 57.9 vs 60.0). Women respondents also reported higher levels of depression (median PHQ-9 score, 11 vs 6 for men). Although these data are consistent with evidence within the general population indicating that women have a higher prevalence of major depression than men, 37 In caregivers of children with hemophilia B, levels of anxiety and depression as measured by PHQ-9 and GAD-7 were found to be greatest in caregivers of children with moderate hemophilia. In addition, mothers reported greater levels of depression and anxiety than fathers, which may be attributed to the higher incidence of major depression in women than men in the general population or may reflect gender-specific differences in management roles or approaches toward coping with their child's disease. 37 These findings highlight the need to increase routine education for caregivers of children with mild-moderate hemophilia and suggest that screening for depression and anxiety in caregivers should be performed on a routine basis. TA B L E 3 PHQ-9 (depression) and GAD-7 (anxiety) in caregivers of children with hemophilia B 
| CON CLUS IONS
The B-HERO-S study provided an opportunity to assess HRQoL among adults with hemophilia B and caregivers of children with hemophilia B. Importantly, the results demonstrate differences in depression and pain among individuals of different hemophilia severities, and differences between women and men with hemophilia.
The outcomes discussed here suggest that complications from pain and depression may mediate the psychosocial impact of hemophilia B as described in previous reports. 11, 12 Taken together, the results from B-HERO-S emphasize the importance of addressing issues related to pain and depression in individuals with hemophilia B, regardless of severity or gender, in order to reduce the psychosocial impact of hemophilia and improve overall HRQoL.
